A Study to Investigate the Efficacy and Safety Profile of GM-XANTHO [GM-XAN003] in Patients with Psoriasis
Phase 2
Not yet recruiting
- Conditions
- Psoriasis
- Interventions
- Drug: 5% GM-XANTHO [GM-XAN003]Drug: Placebo
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Xantho Biotechnology Co., LTD
- Target Recruit Count
- 65
- Registration Number
- NCT06620692
A Study of GM-XANTHO in Pressure Ulcer Patients
- First Posted Date
- 2022-01-20
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Xantho Biotechnology Co., LTD
- Target Recruit Count
- 58
- Registration Number
- NCT05199077
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
A Phase I/IIa Study to Investigate the GM-XANTHO in Healthy Volunteers and Atopic Dermatitis Patients
Phase 1
Completed
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: Placebo onitmentDrug: GM-XANTHO onitment
- First Posted Date
- 2020-04-30
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- Xantho Biotechnology Co., LTD
- Target Recruit Count
- 76
- Registration Number
- NCT04369846
- Locations
- 🇨🇳
Ministry of Health and Welfare Shuang-Ho Hospital, New Taipei, Taiwan
🇨🇳National Taiwan University Hospital, Taipei, Taiwan
🇨🇳Taipei Medical University Hospital, Taipei, Taiwan
© Copyright 2025. All Rights Reserved by MedPath